Top
Main

All Outcomes

Feedback
Home
Show Outline
Top   Main   All Outcomes
Home   COVID-19 treatment studies for Famotidine  COVID-19 treatment studies for Famotidine  C19 studies: Famotidine  Famotidine   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
Loading...
Supplementary Data — Famotidine for COVID-19: real-time meta analysis of 26 studies
Covid Analysis, May 2023
https://c19early.org/fmmeta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Brennan (DB RCT) 48% 0.52 [0.20-1.32] no recov. 5/27 10/28 Improvement, RR [CI] Treatment Control Brennan (DB RCT) 43% 0.57 [0.21-1.55] no recov. 4/19 10/27 Brennan (DB RCT) 28% 0.72 [0.56-0.92] recov. time 27 (n) 28 (n) Shoaibi -3% 1.03 [0.89-1.18] death 1,816 (n) 26,820 (n) Shoaibi -3% 1.03 [0.92-1.15] death/ICU 1,816 (n) 26,820 (n) Zhou (PSM) -81% 1.81 [1.28-2.58] severe case 72/519 198/2,595 Yeramaneni -59% 1.59 [0.94-2.71] death 410 (n) 746 (n) Mura (PSM) 21% 0.79 [0.65-0.96] death 563 (n) 563 (n) Mura (PSM) 37% 0.63 [0.47-0.83] death 305 (n) 305 (n) Samim.. (SB RCT) 33% 0.67 [0.45-0.98] hosp. time 10 (n) 10 (n) Samim.. (SB RCT) 0% 1.00 [0.42-2.40] no recov. 5/10 5/10 Samim.. (SB RCT) 50% 0.50 [0.17-1.46] no recov. 3/10 6/10 Elhadi (ICU) 7% 0.93 [0.73-1.17] death 34/60 247/405 ICU patients Taşdemir 45% 0.55 [0.20-1.55] death 5/85 10/94 OT​1 Taşdemir 37% 0.63 [0.28-1.43] ICU 8/85 14/94 OT​1 Taşdemir 18% 0.82 [0.72-0.93] hosp. time 85 (n) 94 (n) OT​1 Taşdemir 20% 0.80 [0.65-0.99] recov. time 85 (n) 94 (n) OT​1 Kuno (PSM) 0% 1.00 [0.86-1.17] death 1,593 (n) 7,972 (n) Stolow -519% 6.19 [2.10-18.3] death 137 (n) 352 (n) Stolow -2390% 24.90 [3.70-168] ICU 137 (n) 352 (n) Wagner 70% 0.30 [0.20-0.44] death 638 (n) 819 (n) Pahwani (RCT) 11% 0.89 [0.36-2.20] death 8/89 9/89 Pahwani (RCT) 12% 0.88 [0.53-1.45] ventilation 21/89 24/89 Pahwani (RCT) 10% 0.90 [0.51-1.58] ICU 18/89 20/89 Pahwani (RCT) 17% 0.83 [0.79-0.89] hosp. time 89 (n) 89 (n) Pahwani (RCT) 10% 0.90 [0.85-0.96] recov. time 89 (n) 89 (n) Siraj 36% 0.64 [0.48-0.83] death 183/711 122/289 Zangeneh (ICU) 39% 0.61 [0.42-0.90] death n/a n/a ICU patients Chowdhury (RCT) 16% 0.84 [0.54-1.31] death 26/104 31/104 ICU patients Chowdhury (RCT) 9% 0.91 [0.75-1.10] ICU 78 (n) 73 (n) ICU patients Chowdhury (RCT) 33% 0.67 [0.58-0.78] no improv. 78 (n) 73 (n) ICU patients Chowdhury (RCT) 7% 0.93 [0.84-1.03] recov. time 78 (n) 73 (n) ICU patients Chowdhury (RCT) 17% 0.83 [0.72-0.96] hosp. time 78 (n) 73 (n) ICU patients Chowdhury (RCT) 13% 0.87 [0.80-0.95] viral time 78 (n) 73 (n) ICU patients Freedberg (PSM) 57% 0.43 [0.21-0.86] death/int. 8/84 332/1,536 Mather (PSM) 61% 0.39 [0.20-0.74] death 83 (n) 689 (n) Mather (PSM) 50% 0.49 [0.31-0.79] death/int. 83 (n) 689 (n) Balouch 22% 0.78 [0.36-1.51] symp. case 18/80 49/227 Balouch 37% 0.63 [0.26-1.54] recov. time 80 (n) 227 (n) Yeramaneni 51% 0.49 [0.16-1.52] death 351 (n) 6,807 (n) Cheung -34% 1.34 [0.24-6.06] severe case 23 (n) 929 (n) Fung 0% 1.00 [0.96-1.04] death population-based cohort Fung 6% 0.94 [0.91-0.97] hosp. population-based cohort Fung -12% 1.12 [1.10-1.15] cases population-based cohort Razjouyan 27% 0.73 [0.59-0.92] death 93 (n) 9,981 (n) Wallace -11% 1.11 [0.89-1.35] death 98/423 1,436/7,521 MacFadden 7% 0.93 [0.84-1.03] cases n/a n/a Loucera 18% 0.82 [0.59-1.15] death 207 (n) 15,761 (n) Kim 36% 0.64 [0.51-0.80] cases 105/5,594 480/15,432 Famotidine COVID-19 outcomes c19early.org/fm May 2023 1 OT: comparison with other treatment Favors famotidine Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit